Synvista Therapeutics, Inc. 3/A
3/A · Synvista Therapeutics, Inc. · Filed Jan 3, 2008
Insider Transaction Report
Form 3/AAmended
Atticus Capital LP
10% Owner
Holdings
- (indirect: See Note)
Series B Preferred Stock, $0.01 par value per share
Exercise: $2.50→ Common Stock (1,600,000 underlying) - (indirect: See Note)
Series B Preferred Stock Purchase Warrants (right to buy)
Exercise: $2.50Exp: 2012-07-25→ Common Stock (400,000 underlying)
Footnotes (5)
- [F1]The Series B Preferred Stock Purchase Warrants represent the right to buy 400,000 shares of Series B Preferred Stock. Each share of Series B Preferred Stock is convertible into one share of Common Stock.
- [F2]Immediately
- [F3]None
- [F4]This amendment to the Form 3 previously filed on August 20, 2007 by (i) Atticus Holdings LP ("Atticus Holdings"), a Delaware limited partnership formerly known as Atticus Capital LP, (ii) Atticus Management LLC, and (iii) Mr. Timothy R. Barakett ("Mr. Barakett" and, together with Atticus Holdings and Atticus Management LLC, the "Former Reporting Persons"). Due to an internal reorganization completed by the Former Reporting Persons, this amendment is being filed by (x) Atticus Management Limited, a Guernsey company, (y) Atticus Capital LP, a newly formed Delaware limited partnership and (z) Mr. Barakett (collectively, the "Reporting Persons"). For further information on this restructuring please see the Schedule 13D/A filed by the Reporting Persons on January 3, 2008.
- [F5]As a result, each of the Reporting Persons may be deemed to be a beneficial owner of the securities owned by the Funds and Accounts for purposes of Rule 16a-1(a)(1) under the Securities Exchange Act of 1934. The Reporting Persons disclaim beneficial ownership within the meaning of Rule 16a-1(a)(2) under the Securities Exchange Act of 1934 in the securities owned by the Funds and the Accounts except to the extent, if any, of their pecuniary interest therein.